Von Willebrand Disease Clinical Trials 2023

What are the top hospitals conducting von willebrand disease research?

The pursuit of effective treatments and improved understanding of von Willebrand disease has brought together top hospitals across the United States. In Peoria, the Bleeding and Clotting Disorders Institute is at the forefront with two active clinical trials dedicated to this rare bleeding disorder. With a total of five trials conducted since their first recorded study in 2015, their efforts are making significant strides towards better management and care for patients. Cincinnati Children's Hospital Medical Center in Ohio joins the mission, currently conducting two active von Willebrand disease trials and contributing to three previous studies since initiating research in 2017.

In Cleveland, Rainbow Babies and Children's Hospital stands as another prominent institution focusing on von Willebrand disease. Their commitment can be seen through their involvement in two ongoing clinical trials alongside their contributions to two prior investigations starting from 2017. Nationwide Children's Hospital located in Columbus also holds a vital role within this collaborative effort; they too are actively engaged in two current clinical trials while having contributed to three past studies since recording their first trial related to von Willebrand disease back in 2017.

Remarkably joining these esteemed institutions is Loma Linda University Health situated amidst San Bernardino where one active von Willebrand disease trial takes place thus far accompanied by an additional completed investigation paving its path forward which was initiated only recently -in2021.

These hospitals collectively exemplify dedication toward finding solutions for individuals impacted by von Willebrand disease- a condition characterized by impaired blood clotting due to deficiencies or abnormalities of certain proteins. By relentlessly pursuing new knowledge through clinical trials, they strive not only to enhance treatment options but also improve quality of life for those affected by this rare disorder across different communities throughout America

Which are the best cities for von willebrand disease clinical trials?

When it comes to von Willebrand disease clinical trials, several cities have emerged as leaders in research and development. Pittsburgh, Pennsylvania; Cleveland, Ohio; Columbus, Ohio; Peoria, Illinois; and Cincinnati, Ohio are at the forefront of conducting active trials for this condition. These cities are investigating various treatments such as rVWF plus TA, Group I, rFVIII, von Willebrand factor (Recombinant), Open Label Emicizumab among others. Through these ongoing studies across multiple locations in the United States, individuals with von Willebrand disease have access to cutting-edge clinical trials that hold promise for improved management and treatment options.

Which are the top treatments for von willebrand disease being explored in clinical trials?

The quest for effective treatments for von Willebrand disease is ongoing, with several promising options making their way through clinical trials. Among the top contenders in these trials are:

• wilate: This treatment is currently being tested in one active trial specifically targeting von Willebrand disease. It was first listed as a potential therapy in 2021.

• rFVIII: Another hopeful candidate, rFVIII has shown promise and is now undergoing testing in one active clinical trial dedicated to addressing von Willebrand disease. Its initial listing as a potential treatment dates back to 2019.

• Von Willebrand factor (Recombinant): Also garnering attention is the recombinant form of von Willebrand factor, which has demonstrated its potential benefits by appearing in two past trials and currently participating in one ongoing study focused on treating this condition since its introduction as a therapeutic option in 2017.

As research progresses, it brings us closer to finding improved therapies that can enhance the lives of individuals living with von Willebrand disease.

What are the most recent clinical trials for von willebrand disease?

Recent clinical trials have brought forth promising advancements in the field of von Willebrand disease treatment. One such trial is the open-label study evaluating Emicizumab, which has shown potential in managing this condition. Additionally, wilate has undergone Phase 3 testing and exhibits promise as a therapeutic option for individuals with von Willebrand disease. Another notable trial investigated the efficacy of rVWF plus TA, showcasing encouraging results for patients with this disorder. These recent studies highlight significant progress in advancing treatment options and improving outcomes for those living with von Willebrand disease.

What von willebrand disease clinical trials were recently completed?

Recently, there have been notable advancements in clinical trials for von Willebrand disease. In May 2021, Bioverativ, a Sanofi company, successfully completed a trial investigating efanesoctocog alfa (BIVV001) as a potential treatment option. Furthermore, Octapharma concluded their Wilate trial in June 2020. These developments demonstrate the ongoing efforts to improve therapies and enhance the lives of individuals living with von Willebrand disease.